CASE STUDY | PAYER COMMUNICATIONS
When Pediatric Access Risked Delays, We Prepared the Market Ahead of Launch.
THE CHALLENGE
Expanding Access to a New Pediatric Population Without Delaying Launch
A biopharmaceutical company launched a treatment for adults with narcolepsy, achieving strong coverage and pull-through with sleep specialists.
Ahead of a pediatric indication, the company needed to avoid unnecessary denials or access delays at launch. Payers would need to evaluate prior authorization requirements for a new pediatric population, while many prescribers were less familiar with treatment and approval pathways.
THE BREAKTHROUGH
Shifting Access Preparation Upstream to Remove Friction at Launch
Using our Breakthrough Process, powered by 3D Science, BGBx Market Access identified that access risk was driven not by policy alone, but by a lack of early alignment across payers and prescribers.
The strategy shifted access preparation upstream, ensuring prior authorization expectations, prescribing workflows, and access pathways were clearly defined before launch to reduce friction at the point of prescribing.
The Solution
- Pre-Approval Information Exchange enabled payers to anticipate pediatric PA requests
- HCP communications clarified prior authorization requirements and approval pathways
- Field reimbursement and hub support provided targeted guidance to support PA approval
THE RESULTS
Successful Pediatric Launch with Improved PA Execution
Pre-approval and launch investments supported a successful pediatric launch and pull-through. Pediatric PA requests reflected established best practices, submissions were successfully implemented and approved, and PA processes were streamlined at launch.
PIE
Pre-Approval Exchange
Payers aligned before launch
PA
Streamlined Process
Improved execution at launch
HCP
Provider Education
Clearer access pathways
Let’s Build Your Next Market Access Breakthrough
At BGBx, we design access and communication strategies that prepare stakeholders ahead of launch, helping reduce friction and support uptake when it matters most. Let’s build your next breakthrough together.

2026 Oncology Market Access Trends

Implications of the IRA’s Maximum Fair Price (MFP) Negotiations



